Cancer Research and Treatment

A SYSTEMIC ANALYSIS OF OXIDATIVE PATHWAYS OF THE SUGAR IN TUMOR TISSUES: Poong Man Jung; J Korean Cancer Assoc. 1972;7(1):1-15.

Abstract PDF: In order to prove the derangement of the oxidative metabolism of sugar in cancer tissued, the oxidative pathway of glucose and its intermediates was analyzed xyxtematically with human and animal cancer tissued. The results were as follows: 1) Total CO2 production and RSACO2 of sugar were remarkably decreased in cancer tissues. 2) The fractionation of the oxidative pathway of glucose suggested that the decreased production of CO2 from glcose was due to the poor efficiency of the EMP-TCA cycle. 3) The carboxyl carbon of lactate was easily oxidized to CO2 but the oxidation of C-2 and C-3 was suppressed. This suggested that not same amount of CO2 was evolved from each earbon of sugar. Therefore, the following metabolic pattern of glcose was suggested as a common character in cancer tissues. Glucose uptaken by ancer tissues was degraded easily to 3 carbon compound via the anaerobic glycolytic pathway and C-1 of glucose could be easily oxidized to CO2 via the HMP. Further oxidation of 3 carbon compound was still able to be oxidized only for the C-1 by the oxidative decarboxylotion, but the oxidation of C-2 and C-3 of 3 carbon campound was remarkably suppressed. Those findings indicated that the incorporation of 2 carbon ompound into the TCA cycle was suppressed.

TUMORINHIBITORY EFFECT OF BETA - LIPOPROTEIN EXTRACTED FROM HUMAN PLACENTA: Don Seek Chang; J Korean Cancer Assoc. 1972;7(1):15-23.

Abstract PDF: The beta-lipoprotein was isolated from human placenta by means of macromolecular dextran sulfate method, and its tumor inhibitory action on Ehrlich cncer and Sarcoma 180 was studied. The human placental beta-lipoprotein caused marked regression or disappearance of tumor in proortion to the in crement of the injected dose. The possibility that the human placental beta-lipoprotein, like serum beta-lipoprotein, is one of the main components of the tumor inhibitory factor was discussed.

CLINICAL STUDIES ON THE CARCINOLYTIC ACTION OF BOVINE PANCREATIC RIBONUCLEASE: Taik Koo Yun, Yong Kyu Kim, Byung Soo Kim, Heung Kil Park, Soo Sung Park, Chang Soo Koh, Jin Yong Kim, Ki Bok Park; J Korean Cancer Assoc. 1972;7(1):23-49.

Abstract PDF: A few studies on the anti-cancer effects of ribonuclease have been carried out in experimental tumors with a limited success. This study is designed to demonstrate the carcinolytic action of bovine pancreatic ribonuclease in the human subjects. Twenty-three cases with various types of objectively measurable neoplastic diseases such as hemangioendothelioma, squamous cell carcinoma, fibrosarcoma, lymphatic metastastasis of hepatoma, carcinomatous peritonitis, carcinomatous pleurisy, liosarcoma, synovial sarcoma, malignant lymphoma, malignant giant cell tumor, leukemia bronchogenic carcinoma and stomach cancer were selected for the current investigation. Bovine pancreatic ribonuclease was administered by topical, intracavitary, intramuscular and intravenous routes with dose schedule of 1.0 to 3.0 mg per kg of body weight per day for five to thirty-five days. In the group in which the enzyme was topically administered, marked regression or disappearance and carcinolysis of tumors were observed in cases of fibrosarcoma, liposarcoma, synovial sarcoma and in some cases of squamous cell carcinoma. The enzyme itself appeared to have no myelodepressive action. However, allergic shock occurred in two cases after the repeated course of topical administration. It appears from these observations that ribonuclease might be of use as an anticancer agent especially in fibrosarcoma, liposarcoma and synovial sarcoma which are known to be relatively resistant to radiotherapy.

Previous issues